Product
SHR1459
5 clinical trials
5 indications
Indication
Membranous NephropathyIndication
Neuromyelitis Optica Spectrum DisordersIndication
B-cell TumorsIndication
Mature B Cell NeoplasmsIndication
Adult HealthClinical trial
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR1459 Tablets in the Treatment of Primary Membranous Nephropathy (PMN)Status: Active (not recruiting), Estimated PCD: 2023-08-28
Clinical trial
An Open Label Phase II Clinical Trial Evaluating the Efficacy and Safety of SHR1459 in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)Status: Completed, Estimated PCD: 2022-08-15
Clinical trial
Phase 1 Study to Evaluate the Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrentreplased/Refractory Mature B Cell Neoplasms TumorStatus: Active (not recruiting), Estimated PCD: 2023-12-30
Clinical trial
Study of the Pharmacokinetic Effects of Efavirenz on the Pharmacokinetics of SHR1459 in Healthy SubjectsStatus: Completed, Estimated PCD: 2022-12-02
Clinical trial
Pharmacokinetic Evaluation Study of Healthy Chinese Volunteers After Oral Administration of SHR1459 Tablets in Old and New FormulationStatus: Completed, Estimated PCD: 2020-07-11